New combo shows promise for Hard-to-Treat lung cancer
NCT ID NCT05263947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific genetic change (EGFR L858R). The goal was to see if this combo could delay cancer growth better than standard treatment. Participants took the drugs daily until their cancer worsened or side effects became too severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEVACIZUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Could a lifesaving leukemia drug harm Men's sexual health?
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail